James
Reynolds, MD
Staff Clinician
301-496-5675
Dr. James Reynolds’ more recent research has focused on diagnostic imaging and therapy of endocrine tumors including thyroid cancer, gastrinoma and pheochromocytoma with a special interest in radiation dosimetry.
BS, University of Wisconsin
MD, University of Wisconsin
Dr. Reynolds, a native of Madison, Wisconsin, earned his bachelor's and medical degrees from the University of Wisconsin. He trained in internal medicine at the Mayo Clinic and in endocrinology both at Mayo and the Ohio State University. He received nuclear medicine training at the University of Washington, Seattle. He is board certified in all three specialties and is a Certified Clinical Densitometrist (ISCD).
While teaching and practicing endocrinology at Ohio State University, Dr. Reynolds was head of the Department of Medicine clinical endocrinology laboratory. He came to the National Institutes of Health in 1983 as a staff physician and head of the in-vitro laboratory supporting diagnostic and therapeutic studies with radiolabeled monoclonal antibodies. From 1991 to 1999 he was Chief of the Clinical Studies Section of the Nuclear Medicine Department where he currently heads the Densitometry Section.
Dr. Reynolds’ more recent research has focused on diagnostic imaging and therapy of endocrine tumors including thyroid cancer, gastrinoma and pheochromocytoma with a special interest in radiation dosimetry. The densitometry section supports intramural NIH projects in bone densitometry and body composition. Dr. Reynolds currently is a co-investigator of over 40 clinical protocols.
Dr. Reynolds was a member of the NIH Radiation Safety Committee for 11 years and co-chairman from 1997 to 2002. Since 2003 he has been a member of a NICHD data safety and monitoring board for a national study of bone densitometry in children.
Martiniova L, Perera SM, Brouwers FM, Alesci S, Abu-Asab M, Marvelle AF, Kiesewetter DO, Thomasson D, Morris JC, Kvetnansky R, Tischler AS, Reynolds JC, Fojo AT, Pacak K. Increased uptake of [123I]meta-iodobenzylguanidine, [18F]fluorodopamine, and [3H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors. Endocr Relat Cancer. 2011 Jan 13;18(1):143-57.
Choi BY, Muskett J, King KA, Zalewski CK, Shawker T, Reynolds JC, Butman JA, Brewer CC, Stewart AK, Alper SL, Griffith AJ. Hereditary hearing loss with thyroid abnormalities. Adv Otorhinolaryngol. 2011;70:43-9.
Introne WJ, Perry MB, Troendle J, Tsilou E, Kayser MA, Suwannarat P, O'Brien KE, Bryant J, Sachdev V, Reynolds JC, Moylan E, Bernardini I, Gahl WA. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab. 2011 May 6.
King KS, Whatley MA, Alexopoulos DK, Reynolds JC, Chen CC, Mattox DE, Jacobs S, Pacak K. The use of functional imaging in a patient with head and neck paragangliomas. J Clin Endocrinol Metab. 2010 Feb;95(2):481-2.
Wolff EF, Hughes M, Merino MJ, Reynolds JC, Davis JL, Cochran CS, Celi FS. Expression of benign and malignant thyroid tissue in ovarian teratomas and the importance of multimodal management as illustrated by a BRAF-positive follicular variant of papillary thyroid cancer. Thyroid. 2010 Sep;20(9):981-7.
Merideth MA, Gordon LB, Clauss S, Sachdev V, Smith AC, Perry MB, Brewer CC, Zalewski C, Kim HJ, Solomon B, Brooks BP, Gerber LH, Turner ML, Domingo DL, Hart TC, Graf J, Reynolds JC, Gropman A, Yanovski JA, Gerhard-Herman M, Collins FS, Nabel EG, Cannon RO 3rd, Gahl WA, Introne WJ. Phenotype and course of Hutchinson-Gilford progeria syndrome. N Engl J Med. 2008 Feb 7;358(6):592-604.
Zelinka T, Timmers HJ, Kozupa A, Chen CC, Carrasquillo JA, Reynolds JC, Ling A, Eisenhofer G, Lazúrová I, Adams KT, Whatley MA, Widimsky J Jr, Pacak K. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations. Endocr Relat Cancer. 2008 Mar;15(1):311-23.
Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr. 2008 Apr;152(4):582-4.
Hoffman KE, Derdak J, Bernstein D, Reynolds JC, Avila NA, Gerber L, Steinberg SM, Chrousos G, Mackall CL, Mansky PJ. Metabolic syndrome traits in long-term survivors of pediatric sarcoma. Pediatr Blood Cancer. 2008 Feb;50(2):341-6.
Eskandari F, Martinez PE, Torvik S, Phillips TM, Sternberg EM, Mistry S, Ronsaville D, Wesley R, Toomey C, Sebring NG, Reynolds JC, Blackman MR, Calis KA, Gold PW, Cizza G; Low bone mass in premenopausal women with depression. Arch Intern Med. 2007 Nov 26;167(21):2329-36.
Lopez-Granados E, Temmerman ST, Wu L, Reynolds JC, Follmann D, Liu S, Nelson DL, Rauch F, Jain A. Osteopenia in X-linked hyper-IgM syndrome reveals a regulatory role for CD40 ligand in osteoclastogenesis. Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5056-61.
Leong GM, Abad V, Charmandari E, Reynolds JC, Hill S, Chrousos GP, Nieman LK. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J Bone Miner Res. 2007 Jan;22(1):110-8.
Pryor SP, Madeo AC, Reynolds JC, Sarlis NJ, Arnos KS, Nance WE, Yang Y, Zalewski CK, Brewer CC, Butman JA, Griffith AJ. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. J Med Genet. 2005 Feb;42(2):159-65.
Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003 Sep;88(9):4214-20.
Gibril F, Reynolds JC, Chen CC, Yu F, Goebel SU, Serrano J, Doppman JL, Jensen RT, Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localization on management in patients with gastrinomas. J Nucl Med 40: 539-553, 1999.(1999 Society of Nuclear Medicine Award for Outstanding Clinical Research)
Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, Robbins J, Lithium as a potential adjuvant to I-131 therapy of metastatic well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999 84: 912-916.
Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD, Hay ID, Levis S, Reynolds JC, Robbins J, Cavalieri RR, Maxon HR, Mcellin K, Mosciecki, R. Comparison of recombinant human thyrotropin administration with thyroid hormone withdrawal for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337: 888-896, 1999.
Reynolds JC. Comparison of I-131 Absorbed radiation doses in children and adults: A tool for estimating therapeutic I-131 doses in children. Robbins J. Ed., Treatment of Thyroid Cancer in Childhood. Proceedings of a Workshop held Sept 10-11, 1992 at the National Institutes of Health, pp.127-136, 1994.